Dr. David Pedowitz enrolls 1st patient in Integra's Cadence Total Ankle System study: 5 insights

Written by Mackenzie Garrity | September 22, 2017 | Print  |

David Pedowitz, MD, of Philadelphia-based Rothman Institute, implanted the first Cadence Total Ankle System as part of Integra LifeSciences' Cadency Total Ankle System study.

Here are five insights:

 

1. The objective of the study is to evaluate two-year implant survivorship in patients who receive the Cadence Total Ankle System for primary ankle arthroplasty.

 

2. Implant survivorship will be evaluated again at five and 10 years post operatively.

 

3. The Cadence system incorporates features to accommodate various patient anatomies, reduce potential clinical complications and address common challenges associated with ankle arthroplasty procedures.

 

4. Key features of the Cadency Total Ankle System include:

 

• Side specific, anatomical tibial components, designed to void fibular impingement

• Side specific, anatomical talar components, designed to minimize resected talar bone and to preserve vascularity in the ankle

• Bearing insert components for improved wear characteristics

 

5. More than 350 Cadence total ankle procedures have successfully been performed throughout the world.

 


More articles on devices and implants:
Stryker receives FDA clearance for Tritanium C Anterior Cervical Cage: 5 key notes
Global medical robotics market to reach $20B by 2022: 5 takeaways
Beaumont Health 1st in Michigan to evaluate ReActiv8 stimulation system: 5 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months